Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-016: Pembrolizumab in MSI-High Tumors
NCT01876511Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2013
- Primary completion
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in colorectal cancer (CRC), solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT01876511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01876511.